Tyrosine kinase inhibitors Archives - Page 2 of 2

Sprycel Approved in Combination with Chemo in Certain Pediatric Patients with PH+ ALL

Acute Lymphoblastic Leukemia (ALL), Approvals, Biopharmaceutical, Chemotherapy, FDA, FDA/Regulatory, New Indications, Oncology, Pediatric, Priority Review, Tyrosine kinase inhibitors

Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration expanded the indication for Sprycel tablets to include the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.

January 2, 2019/by Business Wire

Europe Approves Expanded Indication for Sprycel

Approvals, European Commission, European Commission, Expanded Approval, FDA/Regulatory, Pediatric, Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML), Tyrosine kinase inhibitors

The European Commission approved Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive CML in chronic phase.

July 5, 2018/by Business Wire